1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The OVTOKO cell line originates from human ovarian clear cell adenocarcinoma, having been established from metastatic tumors in patients previously subjected to five to six courses of CAP chemotherapy. These cells demonstrate morphological heterogeneity, comprising small to moderately sized cuboidal cells, columnar cells, spindle-shaped cells, and malignant tumor giant cells. They consistently exhibit coexpression of cytokeratins and vimentin, indicative of an epithelial origin in culture, specifically expressing cytokeratin polypeptides 7, 8, 18, and 19. Additionally, OVTOKO cells express epidermal growth factor (EGF) receptors but lack estrogen and progesterone receptors. Notably, intraperitoneal transplantation of OVTOKO cells results in peritoneal implantation and distant metastasis, rendering them a valuable model for investigating ovarian cancer progression and therapeutic strategies.
Why choose OVTOKO from AcceGen?
OVTOKO cells from AcceGen exhibit exceptional quality with high viability, ensuring their reliability in research applications. These cells are maintained under stringent sterile conditions, rigorously tested for the absence of bacteria, fungi, and mycoplasma contamination. They are carefully incubated in optimal growth conditions and cryopreserved by skilled operators, guaranteeing their robustness and consistency for various experimental endeavors.
| Species | Human |
| Cat.No | ABC-TC0888 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Spleen |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The OVTOKO cell line serves as a pertinent experimental system, offering a valuable platform for delving into the underlying intrinsic alterations responsible for malignant progression and chemoresistance in ovarian clear cell adenocarcinoma. With its established origins from metastatic tumors in patients who underwent CAP chemotherapy, OVTOKO cells provide researchers with a controlled environment to study the molecular mechanisms and genetic changes contributing to the development of chemoresistance and the progression of this aggressive cancer subtype. This cell line’s unique characteristics make it an indispensable tool for advancing our understanding of ovarian cancer biology and identifying potential therapeutic targets.
